Drawn to Science: T-cell bispecific antibodies

Published on May 31, 2016

At Roche Pharma Research and Early Development, we are working on a novel form of engineered antibodies for cancer immunotherapy that we call T-cell bispecific antibodies. We consider them match-makers between T-Cells and cancer cells. With two handles, they recognize specific markers on the surface of cancer cells. A third handle is designed to hook to T cells, bringing them in close proximity to the cancer cells. The T-cells are then activated to attack the cancer cells. More about cancer immunotherapy: http://www.roche.com/roche-in-cancer-…

More videos on http://www.youtube.com/user/roche